GRI Bio, Inc. (NASDAQ:GRI – Free Report) shares are set to reverse split on the morning of Tuesday, June 18th. The 1-13 reverse split was announced on Tuesday, June 18th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, June 18th.
GRI Bio Trading Down 11.9 %
Shares of GRI opened at 0.23 on Friday. The stock has a 50-day moving average price of 0.40 and a 200-day moving average price of 1.32. GRI Bio has a 12-month low of 0.21 and a 12-month high of 47.95.
GRI Bio (NASDAQ:GRI – Get Free Report) last issued its earnings results on Friday, May 10th. The company reported -0.46 EPS for the quarter.
About GRI Bio
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
See Also
- Five stocks we like better than GRI Bio
- How to Use the MarketBeat Excel Dividend Calculator
- MarketBeat Week in Review – 6/10 – 6/14
- What is the Nikkei 225 index?
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- ETF Screener: Uses and Step-by-Step Guide
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
